Are Incentives Out Of Balance With Patient Need?
Executive Summary
Incentives matter; they motivate us to do things. There is renewed interest in just what motivates the life sciences industry to make the choices it does when determining the diseases it will focus on, and how much effort it puts in. This stems from concern about too much effort going into some areas, and too little in others.
You may also be interested in...
A Look At The New Leadership Team At NICE
The new appointments to the top jobs at NICE may bring continuity at a challenging time for the institute, but perhaps not the real change that some in the industry say is needed.
Focusing On Collaborative Not ‘Innovative’ Ways To Pay
Innovation is defined by the Cambridge dictionary as “(the use of) a new idea or method.” The term is bandied about a great deal in the life sciences industry. Is it actually helpful to use the term so widely, or does the sector risk overlooking true innovation? This can be applied not only to the drugs coming to market, but how they are paid for as well.
UK To Cut Company Payments Under Statutory Pricing Scheme
Companies that are part of the statutory pricing scheme could pay up to £6m less in 2020 under government proposals to cut percentage payments on their sales to the National Health Service.
Need a specific report? 1000+ reports available
Buy Reports